Who is sponsoring NCT03509623?

NCT03509623 is sponsored by University Hospital of Patras.

What drugs are being tested in NCT03509623?

Interventions in NCT03509623: Blood sampling through direct peripheral venous puncture.

What condition does NCT03509623 study?

NCT03509623 studies Neovascular Age-related Macular Degeneration.

Is NCT03509623 still recruiting?

NCT03509623 is currently completed. Last updated 7 May 2018.

Last reviewed 2018-05-07 · How we verify

NCT03509623

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood Coagulation Parameters in Patients Receiving Intravitreal Aflibercept for Age-related Macular Degeneration

Completed NA Last updated 7 May 2018

What this trial tests

NA trial testing Blood sampling through direct peripheral venous puncture in Neovascular Age-related Macular Degeneration in 47 participants. Completed in 27 April 2018.

Timeline

2 August 2017

Primary endpoint
26 March 2018

27 April 2018

Quick facts

Lead sponsor	University Hospital of Patras
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	47
Start date	2 August 2017
Primary completion	26 March 2018
Estimated completion	27 April 2018
Sites	1 location across Greece

Drugs / interventions tested

Blood sampling through direct peripheral venous puncture

Conditions studied

Neovascular Age-related Macular Degeneration — all drugs for Neovascular Age-related Macular Degeneration →

Sponsor

University Hospital of Patras

Who can join

60 and older, any sex, with Neovascular Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate coagulation parameters in treatment naive patients with neovascular age-related macular degeneration (AMD). Treatment naive patients with neovascular AMD, scheduled to undergo treatment with intravitreal injections of aflibercept will be enrolled in the study. Blood samples will be collected before the first intravitreal injection and at 7 and 30 days after aflibercept administration.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of intravitreal injection of aflibercept on blood coagulation parameters in patients with age-related macular degeneration.
Georgakopoulos CD, Makri OE, Pallikari A, Kagkelaris K, et al · · 2020 · cited 4× · PMID 32095777 · DOI 10.1177/2515841420903929

Verify or expand the search:

Other recruiting trials for Neovascular Age-related Macular Degeneration

Currently open trials in the same condition.

NCT07275840 — A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD · Phase 2 · recruiting
NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
NCT07053358 — Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients · EARLY_PHASE1 · recruiting
NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
NCT06495918 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- R · Phase 3 · active not recruiting

Other University Hospital of Patras trials

Trials by the same sponsor.

NCT07250529 — Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF · NA · recruiting
NCT07305194 — Study of AHRE Burden in Patients Undergoing Bachmann Bundle Area Pacing and Left Bundle Branch Pacing. · not yet recruiting
NCT06942260 — Vascular Access Registry · recruiting
NCT05605288 — Distal Versus Conventional Transradial Artery Access for Coronary Catheterization in Patients With STEMI · NA · recruiting
NCT06689111 — Correlation of Typical LBBB Mechanical Activation Pattern by 2D Strain Echocardiography With Acute GWE Improvement in Pa · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03509623 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital of Patras
Last refreshed: 7 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03509623.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing